** Shares of drug developer Protagonist Therapeutics PTGX.O rise 9% to $41 premarket
** PTGX and Takeda 4502.T says its drug to treat a type of blood cancer met the main goal of proportion of patients achieving a response in a late-stage study
** Co says 77% of patients who were treated with the drug, rusfertide, responded to it, compared with 33% that received placebo
** Drug was tested in patients with the rare blood cancer, polycythemia vera, who require regular withdrawal of blood (phlebotomy) to manage their condition
** Co says there was no evidence of an increased risk of cancer in rusfertide-treated patients compared to those on placebo
** PTGX rose 23.5% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。